Scarica l'app Stockscreener
30.74
1.38%
0.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Moderna Inc Borsa (MRNA) Ultime notizie
BDF Gestion Invests $783,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna’s SWOT analysis: mRNA pioneer’s stock faces pivotal moment - Investing.com
Trump administration cancels Moderna contract to fight bird flu and other viruses - Arizona Daily Star
Moderna (MRNA) Sees Bullish Trading Activity with Increased Options Volume | MRNA Stock News - GuruFocus
US Senate Democrats demand Kennedy explain canceling bird flu vaccine contract - MarketScreener
Zika Virus Therapeutics Market Size & Share | Industry Growth [2032] - SkyQuest Technology
AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine - Benzinga
Moderna (MRNA) Sees Bearish Sentiment Among Option Traders | MRNA Stock News - GuruFocus
Insurers likely to cover vaccines without ACIP recommendations - Seeking Alpha
SG Americas Securities LLC Lowers Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Rakuten Securities Inc. Has $742,000 Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Robert F. Kennedy Jr.'s CDC Overhaul 'Critically Weakened' US Vaccine Program, Say Ousted Experts - Benzinga
Moderna Target of Unusually High Options Trading (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Stock Price Down 3.8%Here's What Happened - MarketBeat
Transcript : Moderna, Inc.Special Call - MarketScreener
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Tobam - MarketBeat
Union Bancaire Privee UBP SA Reduces Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna | History, Innovation, Challenges, & Facts - Britannica
FDA approves Moderna’s new COVID-19 vaccine - Santa Clarita Valley Signal
FDA approves expanded use of Moderna’s RSV shot - MSN
Moderna, Inc. (MRNA) stock price, news, quote and history - Yahoo
GAMMA Investing LLC Grows Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna’s SWOT analysis: mrna stock faces challenges amid vaccine shifts - Investing.com
Here's Why Moderna (MRNA) Fell More Than Broader Market - sharewise
Moderna Seeks Outside Investors to Fund Select Vaccine Trials - MSN
FDA expands approval of Moderna’s RSV vaccine to some adults under age 60 - weisradio.com
FDA expands approval of Moderna's RSV vaccine to some adults under age 60 - WBAL News Radio
FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains - The Hill
IBM and Moderna tout use cases for AI in total rewards - HR Brew
Moderna falls on doubts over new CDC panel's backing of RSV vaccine - Reuters
Moderna (MRNA) Faces Challenges Despite RSV Vaccine Approval - GuruFocus
Moderna wins FDA OK to widen use of RSV vaccine - BioPharma Dive
Moderna Stock Falls on CDC Panel Concerns Over RSV VaccineNews and Statistics - IndexBox
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59 - The Boston Globe
Moderna under pressure despite RSV vaccine approval into wider age group - MSN
FDA nod for Moderna’s RSV Vaccine, mRESVIA for younger adults - The Pharma Letter
Moderna (MRNA) Faces Intensified Short Selling Amid Challenges - GuruFocus
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects - TradingView
Moderna Wins Expanded Label for mRNA RSV Shot as New ACIP Members Question mRNA Technology - BioSpace
Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults - Yahoo Finance
Moderna's RSV shot gets US nod for use in younger adults - pharmaphorum
Moderna (MRNA) Gains FDA Approval for Expanded RSV Vaccine Use - GuruFocus
FDA expands Moderna's RSV vaccine approval to at-risk adults (MRNA:NASDAQ) - Seeking Alpha
FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up - Benzinga
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease - Knoxville News Sentinel
Moderna Gets FDA Approval for mRESVIA in Adults Aged 18-59 at Increased Risk for RSV Disease - marketscreener.com
Moderna (MRNA) Receives FDA Nod for RSV Vaccine Extended Use | M - GuruFocus
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):